Assembly Biosciences (ASMB)
NASDAQ:ASMB
ASMB Stock Chart & Stats
$27.70
-$0.45(-2.59%)
At close: 4:00 PM EST
$27.70
-$0.45(-2.59%)
Day’s Range― - ―
52-Week Range$7.75 - $39.71
Previous CloseN/A
Volume7.37K
Average Volume (3M)164.41K
Market Cap
$439.40M
Enterprise Value$383.57M
Total Cash (Recent Filing)$248.11M
Total Debt (Recent Filing)$2.63M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 07, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.39
Shares Outstanding15,862,705
10 Day Avg. Volume178,321
30 Day Avg. Volume164,409
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue5.31
Enterprise Value/Gross Profit6.83
Enterprise Value/Ebitda-37.23
Forecast
1Y Price Target
$45.00Price Target Upside62.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.38
Revenue Forecast (FY)$55.63M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationPhase 1b interim data demonstrated very large reductions in HSV shedding for lead candidates while maintaining placebo-like safety, indicating differentiated potential versus existing therapies.
Development Visibility And Cash RunwayClear plans with ABI-5366 expected to enter Phase 2 in mid-2026 and a cash runway into late 2027 improve visibility around program progression and execution capacity.
Strategic Partnership FundingGilead's opt-in provides a meaningful upfront payment and potential milestone payments, strengthening the company's financial position to advance its antiviral pipeline.
Bears Say
Commercial Adoption UncertaintyUncertainty around commercial adoption of a new antiviral class could limit market uptake even if clinical data are favorable, constraining revenue potential.
Dilution RiskPotential need for additional financing or milestone-driven payments could dilute existing shareholders and impair per-share value.
Regulatory And Manufacturing RiskManufacturing or regulatory delays could push back trial milestones and slow the path to approval, creating downward pressure on valuation.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $7.75 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $439.40M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Mar 19, 2026. The company reported $1.393 earnings per share for the quarter, beating the consensus estimate of -$0.856 by $2.249.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.77.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 15,862,705 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of $1.393 in its last earnings report, beating expectations of -$0.856. Following the earnings report the stock price went up 3.453%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.00 (62.45% Upside)
$45.00 (62.45% Upside)
Hedge Fund Trend
Decreased
By 129.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.70%
12-Months-Change
Fundamentals
Return on Equity
-5.63%
Trailing 12-Months
Asset Growth
115.29%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$45.00
▲(62.45% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---